CAR-T Meeting 2020 | Patient perspectives of CAR T-cell regulation
Natacha Bolaños
• 30 Jan 2020
Natacha Bolaños, Lymphoma Coalition, Madrid, Spain, gives us an overview of the CAR T-cell therapy regulatory session, including the perspectives from the European Medicines Agency (EMA), the Austrian experience on creating a selection algorithm, the importance of post-authorization efficacy and safety studies and the patients’ perspective. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
